FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2334174730> ?p ?o ?g. }

• W2334174730 endingPage "411" @default.
• W2334174730 startingPage "406" @default.
• W2334174730 abstract "In an attempt to limit toxicities associated with dose-intensive therapy used for transplant regimens, we performed a pilot study using amifostine with high-dose busulfan (12 mg/kg), melphalan (100 mg/m2), and thiotepa (500 mg/m2) in 21 patients with a variety of malignancies. After 3 days of oral busulfan, amifostine was given at 910 mg/m2 IV for 10 minutes, preceding the infusion of each of 2 doses of melphalan and thiotepa given for 4 days. Antiemetic premedication for amifostine was given to all patients. The median patient age was 50 years (range: 32-65 years). Twenty-one patients received 82 separate amifostine infusions. One patient discontinued amifostine after the second dose because of severe nausea and emesis, and two infusions were temporarily held secondary to hypotension. Of these 82 cycles, there was a total of 37 episodes of nausea/vomiting, 28 episodes of sneezing, 11 episodes of flushing, and 1 episode of oral paresthesia. Systolic blood pressure and mean arterial pressure decreased by a mean of 8.4 mm Hg and 5.0 mm Hg, respectively. In general, the infusion was well tolerated. Patients were observed until discharge home (N = 15), until initiation of an additional tandem transplant procedure (N = 4), or until death (N = 2). All twenty-one patients experienced nonhematologic toxicities grade II or greater. Grade II toxicities included mucositis (N = 21), gastrointestinal (N = 3), skin (N = 1), and liver (N = 1), and grade III toxicities included liver (N = 1). Mucositis was also scored according to a detailed toxicity assessment. Mucositis did not appear to be improved with amifostine when compared with a control group of patients not receiving amifostine. Renal dysfunction after transplantation was decreased in the amifostine group, whereas there was no significant effect on posttransplant hepatic dysfunction. Although these data demonstrate the feasibility of delivering parenteral amifostine in conjunction with dose-intensive chemotherapy and autologous peripheral blood stem cell transplantation, there was no evidence of a significant reduction in nonmarrow toxicities." @default.
• W2334174730 created "2016-06-24" @default.
• W2334174730 creator A5010023051 @default.
• W2334174730 creator A5023949296 @default.
• W2334174730 creator A5045089433 @default.
• W2334174730 creator A5071375525 @default.
• W2334174730 creator A5072295049 @default.
• W2334174730 creator A5085437967 @default.
• W2334174730 creator A5089559352 @default.
• W2334174730 date "2000-08-01" @default.
• W2334174730 modified "2023-10-01" @default.
• W2334174730 title "Pilot Trial of Cytoprotection With Amifostine Given With High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation" @default.
• W2334174730 cites W107007962 @default.
• W2334174730 cites W137557781 @default.
• W2334174730 cites W1789478788 @default.
• W2334174730 cites W1827459487 @default.
• W2334174730 cites W1954992673 @default.
• W2334174730 cites W1963684703 @default.
• W2334174730 cites W1968334869 @default.
• W2334174730 cites W1975152950 @default.
• W2334174730 cites W1993377906 @default.
• W2334174730 cites W2011744264 @default.
• W2334174730 cites W2014875973 @default.
• W2334174730 cites W2023407694 @default.
• W2334174730 cites W2043356086 @default.
• W2334174730 cites W2071356521 @default.
• W2334174730 cites W2072198722 @default.
• W2334174730 cites W2078490832 @default.
• W2334174730 cites W2084581565 @default.
• W2334174730 cites W2087977674 @default.
• W2334174730 cites W2088074984 @default.
• W2334174730 cites W2089670274 @default.
• W2334174730 cites W2150075625 @default.
• W2334174730 cites W2164157162 @default.
• W2334174730 cites W2165673827 @default.
• W2334174730 cites W2168284025 @default.
• W2334174730 cites W4244166141 @default.
• W2334174730 cites W4249796709 @default.
• W2334174730 cites W71007469 @default.
• W2334174730 doi "https://doi.org/10.1097/00000421-200008000-00019" @default.
• W2334174730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10955873" @default.
• W2334174730 hasPublicationYear "2000" @default.
• W2334174730 type Work @default.
• W2334174730 sameAs 2334174730 @default.
• W2334174730 citedByCount "22" @default.
• W2334174730 countsByYear W23341747302012 @default.
• W2334174730 countsByYear W23341747302015 @default.
• W2334174730 crossrefType "journal-article" @default.
• W2334174730 hasAuthorship W2334174730A5010023051 @default.
• W2334174730 hasAuthorship W2334174730A5023949296 @default.
• W2334174730 hasAuthorship W2334174730A5045089433 @default.
• W2334174730 hasAuthorship W2334174730A5071375525 @default.
• W2334174730 hasAuthorship W2334174730A5072295049 @default.
• W2334174730 hasAuthorship W2334174730A5085437967 @default.
• W2334174730 hasAuthorship W2334174730A5089559352 @default.
• W2334174730 hasConcept C141071460 @default.
• W2334174730 hasConcept C2776694085 @default.
• W2334174730 hasConcept C2776755627 @default.
• W2334174730 hasConcept C2777408962 @default.
• W2334174730 hasConcept C2778496288 @default.
• W2334174730 hasConcept C2778684742 @default.
• W2334174730 hasConcept C2779387952 @default.
• W2334174730 hasConcept C2779968505 @default.
• W2334174730 hasConcept C2780580376 @default.
• W2334174730 hasConcept C2780611847 @default.
• W2334174730 hasConcept C2780852908 @default.
• W2334174730 hasConcept C2780884295 @default.
• W2334174730 hasConcept C2911091166 @default.
• W2334174730 hasConcept C42219234 @default.
• W2334174730 hasConcept C71924100 @default.
• W2334174730 hasConcept C90924648 @default.
• W2334174730 hasConceptScore W2334174730C141071460 @default.
• W2334174730 hasConceptScore W2334174730C2776694085 @default.
• W2334174730 hasConceptScore W2334174730C2776755627 @default.
• W2334174730 hasConceptScore W2334174730C2777408962 @default.
• W2334174730 hasConceptScore W2334174730C2778496288 @default.
• W2334174730 hasConceptScore W2334174730C2778684742 @default.
• W2334174730 hasConceptScore W2334174730C2779387952 @default.
• W2334174730 hasConceptScore W2334174730C2779968505 @default.
• W2334174730 hasConceptScore W2334174730C2780580376 @default.
• W2334174730 hasConceptScore W2334174730C2780611847 @default.
• W2334174730 hasConceptScore W2334174730C2780852908 @default.
• W2334174730 hasConceptScore W2334174730C2780884295 @default.
• W2334174730 hasConceptScore W2334174730C2911091166 @default.
• W2334174730 hasConceptScore W2334174730C42219234 @default.
• W2334174730 hasConceptScore W2334174730C71924100 @default.
• W2334174730 hasConceptScore W2334174730C90924648 @default.
• W2334174730 hasIssue "4" @default.
• W2334174730 hasLocation W23341747301 @default.
• W2334174730 hasLocation W23341747302 @default.
• W2334174730 hasOpenAccess W2334174730 @default.
• W2334174730 hasPrimaryLocation W23341747301 @default.
• W2334174730 hasRelatedWork W1994266890 @default.
• W2334174730 hasRelatedWork W2003697710 @default.
• W2334174730 hasRelatedWork W2033327063 @default.
• W2334174730 hasRelatedWork W2049464048 @default.
• W2334174730 hasRelatedWork W2334174730 @default.
• W2334174730 hasRelatedWork W2413999040 @default.

• next